Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT03917043RecruitingPhase 1
Testing a new targeted drug for ALK or ROS1 lung cancers
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT07752953Recruiting
Personalized immune cell therapy for solid tumors
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
Qinhuangdao, HebeiAges 18–75 - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT07567846RecruitingPhase 1/Phase 2
GDC-1261 Safety and Activity in Advanced Prostate Cancer
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT05991583RecruitingPhase 1/Phase 2
IBB0979 for advanced solid tumors that have stopped responding to treatment
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT07123129RecruitingPhase 1
Study of SHR-7782 for advanced solid tumors
This trial tests a new drug called SHR-7782 for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07038005RecruitingPhase 1
Testing a new drug SPGL008 for advanced solid tumors
This trial tests an experimental drug called SPGL008 in people with advanced solid tumors that have spread or cannot be removed. It is a first-in-human study to learn about safety, dosing, and how the drug works.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07043751RecruitingPhase 1
TQB6411 for advanced solid tumors
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Beijing, Beijing MunicipalityAges 18–75 - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,520 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.